China is moving forward with two more COVID-19 vaccines in the regulatory process, one from the state-owned Sinopharm and one from the private company CanSino.
Both vaccines have been submitted to regulators for approval this week. CanSino said Chinese regulators are reviewing their application for the COVID-19 vaccine, in a file filed Wednesday.
Sinopharm’s subsidiary, the Wuhan Institute of Biological Products, announced on Wednesday that it had filed an application on Sunday and regulators were reviewing it.
China has already approved two vaccines it has used in a massive immunization campaign. One of them is also from Sinopharm, but developed by its subsidiary in Beijing. The other is the Sinovac vaccine.
Sinopharm’s Wuhan incorporation is 72.51% effective, the company said. Both Sinopharm injections are based on inactivated viruses, a traditional technology.
The CanSino vaccine is a single dose injection that relies on a harmless cold virus called adenovirus to deliver the spike gene for the virus into the body. The technology is comparable to the Astrazeneca and Johnson & Johnson vaccines, which rely on different adenoviruses.
CanSino’s vaccine is 65.28% effective, the company said Wednesday.
No company has published the data of their studies in peer-reviewed scientific journals to date.